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Background
ARC1779 is an aptamer which blocks the A1 domain
binding of the von Willebrand Factor (vWF) A1 domain
to platelet glycoprotein (GP) Ib receptors. vWF is
increased in the elderly and in the setting of AMI, as
reflected in higher vWF levels in circulation and in
increased shear-dependent platelet function as measured
by the platelet function analyzer (PFA-100) and cone and
plate analyzer (IMPACT). Conventional therapy of AMI
partially reduces platelet activation and aggregation, but
does not address excessive vWF activity or platelet adhe-
sion.
Methods
We studied the ex vivo dose response curves for ARC1779
on PFA-100 and IMPACT platelet function tests, agonist-
induced platelet aggregation, and vWF ristocetin cofactor
activity (vWF:RiCO; free A1 domain sites) of patients with
AMI on standard treatment including aspirin and clopi-
dogrel (n = 40), young (n = 20) and elderly controls (n =
20).
Results
AMI patients displayed ~2-fold increased plasma levels of
VWF:RiCO as compared to controls. Nevertheless, the
IC50 and IC100 indicate that comparable ARC1779 concen-
trations were needed in AMI patients and controls to sup-
press vWF-dependent platelet plug formation under high
sheer rates (IC50 and IC100 for CADP-CT in hirudinized
blood: ~1.6 to ~2.8 μg/mL (IC50) and ~2.9 to ~3.9 μg/mL
(IC100)). Concomitant anti-platelet therapy (aspirin and
clopidogrel) in AMI patients could be responsible for this
finding. In contrast to GPIIb/IIIa antagonists, ARC1779
did not inhibit platelet aggregation by ADP, collagen or
arachidonic acid as measured by impedance aggregometry
at concentrations (10 μg/mL) that fully inhibited vWF-
dependent platelet function.
Conclusion
ARC1779 potently and specifically inhibits vWF activity
and vWF-dependent platelet function, even in the setting
of AMI where vWF activity is increased.
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